Trial Outcomes & Findings for A Multiple-Dose Study of LY3502970 in Healthy Participants (NCT NCT05110794)
NCT ID: NCT05110794
Last Updated: 2026-05-26
Results Overview
PK: Cmax of LY3502970.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
34 participants
Primary outcome timeframe
PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
Results posted on
2026-05-26
Participant Flow
During the titration period, participants received increasing doses of LY3502970 administered orally every 7 days on Day 1 to Day 21. Upon completion of the titration period, participants were randomized to Fasted state or Fed state sequence of Day 22.
Participant milestones
| Measure |
2 Milligram (mg)/4 mg/8 mg LY3502970
Dose Titration Period: Participants received increasing doses (2 mg, 4 mg, 8 mg) of LY3502970 administered orally every 7 days on Day 1 to Day 21. Participants were randomized to Fasted/Fed state sequence on Day 22.
|
16 mg LY3502970 (Fasted/Fed)
Test Period 1: Participants received 16 mg LY3502970 administered orally every day (QD), Day 22 to Day 28 in Fasted state.
Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fed state.
|
16 mg LY3502970 (Fed/Fasted)
Test Period 1: Participants received 16 mg LY3502970 administered orally QD, Day 22 to Day 28 in Fed state.
Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fasted state.
|
|---|---|---|---|
|
Titration Period
STARTED
|
34
|
0
|
0
|
|
Titration Period
Received at Least One Dose of Study Drug
|
33
|
0
|
0
|
|
Titration Period
COMPLETED
|
29
|
0
|
0
|
|
Titration Period
NOT COMPLETED
|
5
|
0
|
0
|
|
Test Period 1
STARTED
|
0
|
15
|
14
|
|
Test Period 1
Received at Least One Dose of Study Drug
|
0
|
15
|
14
|
|
Test Period 1
COMPLETED
|
0
|
13
|
13
|
|
Test Period 1
NOT COMPLETED
|
0
|
2
|
1
|
|
Test Period 2
STARTED
|
0
|
13
|
13
|
|
Test Period 2
Received at Least One Dose of Study Drug
|
0
|
13
|
13
|
|
Test Period 2
COMPLETED
|
0
|
13
|
13
|
|
Test Period 2
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
2 Milligram (mg)/4 mg/8 mg LY3502970
Dose Titration Period: Participants received increasing doses (2 mg, 4 mg, 8 mg) of LY3502970 administered orally every 7 days on Day 1 to Day 21. Participants were randomized to Fasted/Fed state sequence on Day 22.
|
16 mg LY3502970 (Fasted/Fed)
Test Period 1: Participants received 16 mg LY3502970 administered orally every day (QD), Day 22 to Day 28 in Fasted state.
Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fed state.
|
16 mg LY3502970 (Fed/Fasted)
Test Period 1: Participants received 16 mg LY3502970 administered orally QD, Day 22 to Day 28 in Fed state.
Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fasted state.
|
|---|---|---|---|
|
Titration Period
Adverse Event
|
5
|
0
|
0
|
|
Test Period 1
Adverse Event
|
0
|
1
|
0
|
|
Test Period 1
Withdrawal by Subject
|
0
|
1
|
0
|
|
Test Period 1
Physician Decision
|
0
|
0
|
1
|
Baseline Characteristics
A Multiple-Dose Study of LY3502970 in Healthy Participants
Baseline characteristics by cohort
| Measure |
2 mg/4 mg/8/ mg LY3502970
n=34 Participants
Dose Titration Period: Participants received increasing doses (2 mg, 4 mg, 8 mg) of LY3502970 administered orally every 7 days on Day 1 to Day 21. Participants were randomized to Fasted/Fed state sequence on Day 22.
|
|---|---|
|
Age, Continuous
|
42.8 years
STANDARD_DEVIATION 10.2 • n=20 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
30 Participants
n=20 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Asian
|
34 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
|
Region of Enrollment
Singapore
|
34 Participants
n=20 Participants
|
PRIMARY outcome
Timeframe: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)Population: All participants who received LY3502970 in fed and fasted state and had evaluable PK samples, per protocol.
PK: Cmax of LY3502970.
Outcome measures
| Measure |
16 mg LY3502970 (Fasted)
n=26 Participants
Participants received 16 mg LY3502970 administered orally QD, in the fasted state.
|
16 mg LY3502970 (Fed)
n=25 Participants
Participants received 16 mg LY3502970 administered orally QD, in Fed state.
|
|---|---|---|
|
PK: Maximum Observed Concentration (Cmax) of LY3502970
|
80.5 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 64
|
67.5 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 40
|
PRIMARY outcome
Timeframe: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)Population: All participants who received LY3502970 in fed and fasted state and had evaluable PK samples, per protocol.
PK: AUC0-24 of LY3502970.
Outcome measures
| Measure |
16 mg LY3502970 (Fasted)
n=26 Participants
Participants received 16 mg LY3502970 administered orally QD, in the fasted state.
|
16 mg LY3502970 (Fed)
n=25 Participants
Participants received 16 mg LY3502970 administered orally QD, in Fed state.
|
|---|---|---|
|
PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970
|
1200 ng*hour(h)/mL
Geometric Coefficient of Variation 58
|
1050 ng*hour(h)/mL
Geometric Coefficient of Variation 40
|
PRIMARY outcome
Timeframe: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)Population: All participants who received LY3502970 in fed and fasted state and had evaluable PK samples, per protocol.
PK: Tmax of LY3502970
Outcome measures
| Measure |
16 mg LY3502970 (Fasted)
n=26 Participants
Participants received 16 mg LY3502970 administered orally QD, in the fasted state.
|
16 mg LY3502970 (Fed)
n=25 Participants
Participants received 16 mg LY3502970 administered orally QD, in Fed state.
|
|---|---|---|
|
Time to Maximum Observed Concentration (Tmax) of LY3502970
|
8.0 hour
Interval 4.0 to 16.0
|
8.00 hour
Interval 4.0 to 24.0
|
Adverse Events
2 Milligram (mg) LY3502970 QD
Serious events: 0 serious events
Other events: 27 other events
Deaths: 0 deaths
4 mg LY3502970 QD
Serious events: 0 serious events
Other events: 15 other events
Deaths: 0 deaths
8 mg LY3502970 QD
Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths
16 mg LY3502970 QD (Fasted)
Serious events: 0 serious events
Other events: 18 other events
Deaths: 0 deaths
16 mg LY3502970 QD (Fed)
Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
2 Milligram (mg) LY3502970 QD
n=33 participants at risk
2 mg LY3502970 administered orally every day (QD), Day 1 to Day 8.
|
4 mg LY3502970 QD
n=30 participants at risk
4 mg LY3502970 administered orally QD, Day 8 to Day 15
|
8 mg LY3502970 QD
n=30 participants at risk
8 mg LY3502970 administered orally QD, Day 15 to Day 22.
|
16 mg LY3502970 QD (Fasted)
n=28 participants at risk
16 mg LY3502970 administered orally QD (fasted).
|
16 mg LY3502970 QD (Fed)
n=27 participants at risk
16 mg LY3502970 administered orally QD (fed).
|
|---|---|---|---|---|---|
|
Gastrointestinal disorders
Constipation
|
3.0%
1/33 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.0%
3/30 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Diarrhoea
|
6.1%
2/33 • Number of events 4 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
6.7%
2/30 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.1%
2/28 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.4%
2/27 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.1%
2/28 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.0%
3/30 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Abdominal distension
|
18.2%
6/33 • Number of events 7 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
6.7%
2/30 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
6.7%
2/30 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
14.3%
4/28 • Number of events 5 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
11.1%
3/27 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Nausea
|
36.4%
12/33 • Number of events 15 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.0%
3/30 • Number of events 4 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.0%
3/30 • Number of events 5 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
14.3%
4/28 • Number of events 6 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
18.5%
5/27 • Number of events 6 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Gastrointestinal disorders
Vomiting
|
33.3%
11/33 • Number of events 25 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
13.3%
4/30 • Number of events 7 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
13.3%
4/30 • Number of events 6 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.1%
2/28 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.4%
2/27 • Number of events 6 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Catheter site bruise
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.4%
2/27 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Catheter site erythema
|
3.0%
1/33 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.7%
3/28 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
11.1%
3/27 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Catheter site pain
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Catheter site phlebitis
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Catheter site swelling
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Pain
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
6.7%
2/30 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Pyrexia
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
6.7%
2/30 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
General disorders
Vessel puncture site bruise
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Infections and infestations
Catheter site infection
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
54.5%
18/33 • Number of events 19 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
13.3%
4/30 • Number of events 4 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
6.7%
2/30 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.7%
3/28 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 2 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Nervous system disorders
Headache
|
27.3%
9/33 • Number of events 10 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
10.0%
3/30 • Number of events 4 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
14.3%
4/28 • Number of events 5 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
7.4%
2/27 • Number of events 3 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Nervous system disorders
Lethargy
|
3.0%
1/33 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.3%
1/30 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Nervous system disorders
Syncope
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/28 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.7%
1/27 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
|
Vascular disorders
Hot flush
|
0.00%
0/33 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/30 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
3.6%
1/28 • Number of events 1 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
0.00%
0/27 • Baseline up to Day 49
All participants who are exposed to study intervention LY3502970. Participants will be analyzed according to the intervention they actually received.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place